<PAGE>
Total Number of Pages: 3
--
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: August 13, 1999
Commission File Number: 0-26208
================================================================================
KERAVISION, INC.
(Exact name of Registrant as specified in its Charter)
DELAWARE 77-0328942
(State of Incorporation) (I.R.S. Employer
Identification No.)
48630 MILMONT DRIVE
FREMONT, CA 94538
(Address of principal executive offices)
(510) 353-3000
(Registrant's telephone number)
<PAGE>
ITEM 5. OTHER EVENTS
On August 12, 1999, KeraVision, Inc. announced Common Stock Offering.
Further details regarding this announcement are contained in the Comapny's news
release dated August 12, 1999 attached as exhibit hereto and incorporated
reference herein.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS
(a) Exhibits:
99.28 KeraVision, Inc. News Release dated August 12, 1999
2
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KERAVISION, INC.
/s/Mark Fischer-Colbrie
-----------------------
Mark Fischer-Colbrie
Vice President, Finance and
Administration and Chief Financial
Officer(Principal Financial and
Accounting Officer)
Date: August 13, 1999
3
<PAGE>
Exhibit 99.28
KERAVISION ANNOUNCES COMMON STOCK OFFERING
Fremont, California (August 12, 1999) - KeraVision, Inc. (Nasdaq: KERA)
announced today that it has offered 4 million shares of its common stock
at a price of $13.00 per share. The offering was underwritten by
Donaldson, Lufkin & Jenrette; Dain Rauscher Wessels, a division of Dain
Rauscher Inc.; Prudential Vector Healthcare Group, a unit of Prudential
Securities; and SG Cowen.
All of the shares are to be issued and sold by KeraVision. The net
proceeds from the offering of approximately $48.2 million will be used
by KeraVision for sales and marketing efforts related to the U.S. launch
of IntacsT corneal ring segments, the continued development and clinical
testing of products based on the Intacs technology, prepayment of short-
term debt and for working capital and other general corporate purposes.
KeraVision is developing a new category of non-laser vision correction
products for the treatment of common vision disorders, including myopia
(nearsightedness), hyperopia (farsightedness) and astigmatism, to offer
an alternative to eyeglasses, contact lenses and other vision correction
surgical procedures. KeraVision's first product, Intacs corneal ring
segments, has been approved by the FDA for correcting mild myopia.
Note to Editors: Intacs are a registered trademark or trademark of
KeraVision, Inc. in the U.S. and foreign countries.
Contact:
KeraVision, Inc., Fremont
Mark Fischer-Colbrie, 510/353-3000 (Investors)
Mick Taylor, 510/353-3075 (Media)
www.keravision.com
Fax on Demand, 800/448-8559
